Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis: Bryan Dechairo, Roald Borré

Biocartis said this week that Roald Borré has resigned as director of the company, and Bryan Dechairo has been appointed as a new independent board member and a member of the company's audit committee. Dechairo is CEO of Sherlock Biosciences and serves on that company's board of directors. Prior to joining Sherlock, Dechairo was executive VP of clinical development at Myriad Genetics. Before that, he was chief medical officer, CSO, and senior VP of R&D at Assurex Health, which Myriad acquired in 2016. Earlier, Dechairo held roles of increasing responsibility at companies including Medco, Pfizer, Oxagen, Sequana and Roche. He holds a PhD in common complex human genetics from the Institute of Child Health at University College London and a BA in integrative biology from the University of California, Berkeley.

The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.